This message was sent to the AIM, Health Systems, INE, IAP, MACI, MACI 2, PH Imms Leads, Imms All Staff, MSMS, and DSO All Staff listservs. Apologies for any duplication.

Hello Immunization Partners,

Please share the following information with providers in your jurisdiction.

On August 19, 2024, the Food and Drug Administration (FDA) approved a new dosing schedule for the Meningococcal Group B Vaccine (BEXSERO®) for individuals 10 through 25 years of age. The Advisory Committee on Immunization Practices (ACIP) is anticipated to consider the new schedule at its October 2024 meeting. In the interim, healthcare providers should refer to the updated package insert for new dosing and schedule intervals.

Revised Dose and Schedule: The choice of dosing schedule may depend on the risk of exposure and the individual's susceptibility to meningococcal serogroup B disease.

Two-Dose Schedule:

• Administer a dose (0.5 mL) at 0 and 6 months. If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose.

Three-Dose Schedule:

• Administer a dose (0.5 mL) at 0, 1-2, and 6 months.

Currently, the Michigan Department of Health and Human Services (MDHHS) Division of Immunization is in discussion with the Michigan Care Improvement Registry (MCIR) to ensure accurate assessment and forecasting for BEXSERO®.

We will continue to update our partners on this topic.

Thank you for all you do!

Your Immunization Outreach and Education Team,
Alyssa, Andrea, Dianne, Heidi, Lisa, and Sarah